Distinct antigenic subtypes of human ß interferon can be distinguished by neutralization

Brazilian Journal of Medical and Biological Research

Volumn 29, Issue 10, 1996, Pages 1317-1320

  Golgher, R R ^a   Kroon, E G ^b   Ferreira, P C P ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Amniotic interferon; Antibody neutralization; Antigenic subtype; Human interferon; NIH antiserum to interferon

Indexed keywords

BETA INTERFERON;

AMNION FLUID; ANTIGENIC VARIATION; ARTICLE; FIBROBLAST; HUMAN; IMMUNOLOGY; SERODIAGNOSIS;

AMNIOTIC FLUID; ANTIGENIC VARIATION; FIBROBLASTS; HUMANS; INTERFERON-BETA; NEUTRALIZATION TESTS;

EID: 0030252993     PISSN: 0100879X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Stewart II WE (1981). The Interferon System. 2nd edn. Springer Verlag, New York.
2. Adolf GR, Frühbeis B, Hauptmann R, Kalsner I, Maurer-Fogy I, Ostermann E, Patzelt E, Schwendenwein R, Sommergruber W & Söphel A (1991). Human interferon ω1 : isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein. Biochimica et Biophysica Acta, 1089: 167-174.
3. Whaley AE, Meka CSR, Harbison LA, Hunt JS & Imakawa K (1994). Identification and cellular localization of unique Interferon mRNA from human placenta. Journal of Biological Chemistry, 269: 10864-10868.
4. Ijzermans JNN & Marquet RL (1989). Interferon γ: a review. Immunobiology, 179: 456-473.
5. Dron M & Tovey MG (1992). Interferon αl ß, gene structure and regulation. In: Baron S, Coppenhaver DH, Dianzani F, Fleishmann Jr WR, Hughes Jr TK, Kumpel GR, Niesel DW, Stanton GJ & Tyring SK (Editors), Interferon, Principles and Medical Applications. The University of Texas Medical Branch, Galveston, TX.
6. Kagawa Y, Takasaki S, Utsumi J, Hosoi K, Shimizu H, Kochibe N & Kobata A (1988). Comparative study of the asparaginelinked sugar chains of natural human interferon-ß1 and recombinant human interferon-ß1 produced by three different mammalian cells. Journal of Biological Chemistry. 262: 17508-17515.
7. Ferreira PCP, Paucker M, Golgher RR & Paucker K (1981). Affinity chromatography of human amnion interferon. Archives of Virology, 68: 27-33.
8. Ferreira PCP, Pimenta CG, Kroon EG, Bicalho HMS & Golgher RR (1991). Partial characterization of human amniotic membrane interferon. Brazilian Journal of Medical and Biological Research, 24: 21-27.
9. Reis LFL, Santos JR, Ferreira PCP, Kroon EG & Golgher RR (1989). Antigenic characterization of human interferon derived from amniotic membranes induced by virus. Journal of Interferon Research, 9: 573-581.
10. Tanigushi T, Guarente L, Roberts TM, Kimelman D, Douhan III J & Ptashne M (1980). Expression of the human fibroblast interferon gene in Escherichia coli. Proceedings of the National Academy of Sciences, USA, 77: 5230-5233.
11. Cartwright T, Senussi O & Grady MD (1977). Reagents that inhibit disulfide bond formation stabilize human fibroblast interferon. Journal of General Virology, 36: 323-327.
12. Geigert J, Panschar BM, Fong S, Huston HN, Wong DE, Wong DY, Taforo C & Pemberton M (1988). The long-term stability of recombinant (serine-17) human interferon-β. Journal of Interferon Research, 8: 539-547.
13. The IFNB Multiple Sclerosis Group (1993). Interferon ß-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43: 655-661.
14. Kawade Y (1986). Quantitation of neutralization of interferon by antibody. In: Pestka S (Editor), Interferons. Part C. Methods in Enzymology. Academic Press, New York.
15. Vallbracht A, Treuner J, Flehmig B, Joester KE & Niethammer D (1981). Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature, 289: 496-497.
16. Antonelli G, Currenti M, Turriziani O & Dianzani F (1991). Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. Journal of Infectious Diseases, 163: 882-885.
17. Quesada JR (1992). Toxicity and side effects of interferons. In: Baron S, Coppenhaver DH, Dianzani F, Fleishmann Jr WR, Hughes Jr TK, Klimpel GR, Niesel DW, Stanton GJ & Tyring SK (Editors), Interferon, Principles and Medical Applications. The University of Texas Medical Branch, Galveston, TX.
18. Colby CB, Inoue M, Thompson M & Tan YH (1984). Immunologic differentiation between E coli and CHO cell-derived recombinant and natural human β-interferons. Journal of Immunology, 133: 3091-3095.
19. Redlich PN & Grossberg SE (1989). Analysis of antigenic domains on natural and recombinant human IFN-β by the inhibition of biologic activities with monoclonal antibodies. Journal of Immunology, 143: 1887-1893.
20. National Institutes of Health. National Institute of Allergy and Infectious Diseases. Research Resources Branch (1981). Sheep antiserum to human fibroblast interferon. Research Reference Reagent Note #24.
21. Dalton B & Paucker K (1981). Preparation and adsorption of antiserum against human leukocyte interferon. In: Pestka S (Editor). Interferons. Part B. Methods in Enzymology. Academic Press, New York.